华兰疫苗跌3.48% 2022年上市见顶募22.76亿元

Core Viewpoint - Hualan Vaccine's stock is currently trading at 21.90 yuan, reflecting a decline of 3.48% and is in a state of breaking below its initial public offering price [1] Group 1: IPO and Stock Performance - Hualan Vaccine was listed on the Shenzhen Stock Exchange's ChiNext board on February 18, 2022, with an initial offering price of 56.88 yuan per share and a total of 40.01 million shares issued [1] - On its first trading day, Hualan Vaccine reached an intraday high of 79.78 yuan [2] - The total funds raised from the initial public offering amounted to 2.276 billion yuan, with a net amount of 2.244 billion yuan after deducting issuance costs of 31.5657 million yuan [2] Group 2: Fund Utilization and Financial Details - The funds raised were intended for several projects, including the development and industrialization of flu vaccines, rabies vaccines, multi-component bacterial vaccines, and new pneumonia vaccines, as well as the establishment of a new vaccine research platform [2] - The total issuance costs for the IPO were 31.5657 million yuan, with Huatian United Securities receiving a total of 22 million yuan in underwriting and sponsorship fees [2] Group 3: Dividend Distribution - On May 30, 2023, Hualan Vaccine announced its 2022 annual equity distribution plan, which includes a cash dividend of 3.00 yuan for every 10 shares held and a capital reserve conversion of 5 additional shares for every 10 shares held [2] - The record date for this equity distribution is set for June 6, 2023, with the ex-dividend date on June 7, 2023 [2]